Prof Marianne Carvalho , Dr. Allan Martins-de-Barros , Prof. Fábio Araújo , Mr.s Julliana Carvalho , Dr. Tatiane Faro , Prof. Emanuel Dias
{"title":"BRAF V600E MUTATIONAL STATUS DOES NOT CORRELATE WITH BIOLOGIAL BEHAVIOR IN CONVENTIONAL AMELOBLASTOMAS: A DISEASE-FREE SURVIVAL ANALYSIS","authors":"Prof Marianne Carvalho , Dr. Allan Martins-de-Barros , Prof. Fábio Araújo , Mr.s Julliana Carvalho , Dr. Tatiane Faro , Prof. Emanuel Dias","doi":"10.1016/j.oooo.2024.04.069","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Ameloblastomas, a type of odontogenic tumor, exhibit the BRAF V600E mutation in more than 65% of cases. This study aims to explore the potential correlation between the BRAF V600E mutation, the biological behavior of conventional ameloblastomas, and Disease-Free Survival in patients.</p></div><div><h3>Materials and Methods</h3><p>This retrospective cohort study, following STROBE recommendations, involved individuals treated for conventional ameloblastomas. Clinical, imaging, histomorphological, immunohistochemical (Ki67 and CD138/syndecan-1), and molecular BRAF V600E mutation analyses were conducted. Bivariate statistical analysis employed chi-square and Fisher's exact tests. Kaplan-Meier analysis with log-rank test and Cox proportional hazards regression identified disease-free survival predictors at a 5% significance level.</p><p>The study included 41 individuals, with a male-to-female ratio of 1.15:1. The BRAF V600E mutation was present in 75.6% of tumors. No significant associations were found between BRAF mutational status and other clinical, imaging, histomorphological, and immunohistochemical variables. Univariate (p = 0.008) and multivariate (p = 0.030) analyses revealed that the initial treatment modality significantly influenced prognosis, favoring radical treatment with a Hazard Ratio of 9.60 (95%IC = 1.24 – 73.89).</p></div><div><h3>Conclusions</h3><p>BRAF V600E mutation emerges as a prevalent molecular aberration in ameloblastomas. Nevertheless, it does not seem to significantly affect the tumor proliferative activity, CD138/syndecan-1-mediated cell adhesion, and disease-free survival outcomes.</p></div>","PeriodicalId":49010,"journal":{"name":"Oral Surgery Oral Medicine Oral Pathology Oral Radiology","volume":"138 2","pages":"Page e53"},"PeriodicalIF":2.0000,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Surgery Oral Medicine Oral Pathology Oral Radiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212440324002463","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Ameloblastomas, a type of odontogenic tumor, exhibit the BRAF V600E mutation in more than 65% of cases. This study aims to explore the potential correlation between the BRAF V600E mutation, the biological behavior of conventional ameloblastomas, and Disease-Free Survival in patients.
Materials and Methods
This retrospective cohort study, following STROBE recommendations, involved individuals treated for conventional ameloblastomas. Clinical, imaging, histomorphological, immunohistochemical (Ki67 and CD138/syndecan-1), and molecular BRAF V600E mutation analyses were conducted. Bivariate statistical analysis employed chi-square and Fisher's exact tests. Kaplan-Meier analysis with log-rank test and Cox proportional hazards regression identified disease-free survival predictors at a 5% significance level.
The study included 41 individuals, with a male-to-female ratio of 1.15:1. The BRAF V600E mutation was present in 75.6% of tumors. No significant associations were found between BRAF mutational status and other clinical, imaging, histomorphological, and immunohistochemical variables. Univariate (p = 0.008) and multivariate (p = 0.030) analyses revealed that the initial treatment modality significantly influenced prognosis, favoring radical treatment with a Hazard Ratio of 9.60 (95%IC = 1.24 – 73.89).
Conclusions
BRAF V600E mutation emerges as a prevalent molecular aberration in ameloblastomas. Nevertheless, it does not seem to significantly affect the tumor proliferative activity, CD138/syndecan-1-mediated cell adhesion, and disease-free survival outcomes.
期刊介绍:
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology is required reading for anyone in the fields of oral surgery, oral medicine, oral pathology, oral radiology or advanced general practice dentistry. It is the only major dental journal that provides a practical and complete overview of the medical and surgical techniques of dental practice in four areas. Topics covered include such current issues as dental implants, treatment of HIV-infected patients, and evaluation and treatment of TMJ disorders. The official publication for nine societies, the Journal is recommended for initial purchase in the Brandon Hill study, Selected List of Books and Journals for the Small Medical Library.